[Acceptance and subjective well-being with a norgestimate combination pill].

A combination oral contraceptive (OC) called Cileste containing norgestimate and 35 mcg ethinyl estradiol was assessed in a study involving 46 gynecologists and their patients by administering a questionnaire about acceptance before treatment (first evaluation) and during the 4th cycle of its use (second evaluation). 683 subjects were enrolled: 424 patients took part in a comprehensive evaluation. 379 cases were fully analyzed. The average age was 25.4 years. 14.2 had completed mandatory schooling 39.6% had graduated from apprentice or trade school and 42.2% had graduated from secondary school or college. 38.8% were smokers. 13.7% had spotting; amenorrhea was rare in 10.8% and frequent in 3.4%; 22.4% had light and 14% had strong dysmenorrhea. 63.3% of participants rated Cileste very good 23% rated it good and 3.4% rated it middling (a low figure compared to the 10.6% middling rating of Trinovum users). 15.6% of 379 patients had strong bleeding at first evaluation vs. 4.7% at the second evaluation. 10% and 2.6% had strong dysmenorrhea respectively. 33.7% of 377 patients had signs of depression at the first evaluation vs. 22% of 369 patients at the second assessment. Skin impurities and fatty hair associated with acne were side effects in 22.5% of 378 patients during the first evaluation and in 10.8% of 369 patients at the second evaluation. 28.2% of 638 patients at the first evaluation as compared to 15.6% of 425 patients at the second evaluation agreed that medication should be avoided in conditions of environmental pollution. The decrease was probably attributable to lack of side effects after 4 months of OC use. Women complaining of skin problems often suffered from stronger dysmenorrhea during the first phase. Strong bleeding and depression were also interrelated. Cileste also improved skin blemishes and fatty hair thus during the second evaluation fewer patients complained of depressive symptoms.